Literature DB >> 9837732

The fibronectin type III domain as a scaffold for novel binding proteins.

A Koide1, C W Bailey, X Huang, S Koide.   

Abstract

The fibronectin type III domain (FN3) is a small autonomous folding unit which occurs in many animal proteins involving in ligand binding. The beta-sandwich structure of FN3 closely resembles that of immunoglobulin domains. We have prepared a phage display library of FN3 in which residues in two surface loops were randomized. We have selected mutant FN3s which bind to a test ligand, ubiquitin, with significant affinities, while the wild-type FN3 shows no measurable affinity. A dominant clone was expressed as a soluble protein and its properties were investigated in detail. Heteronuclear NMR characterization revealed that the selected mutant protein retains the global fold of FN3. It also has a modest conformational stability despite mutations at 12 out of 94 residues. These results clearly show the potential of FN3 as a scaffold for engineering novel binding proteins. Copyright 1998 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9837732     DOI: 10.1006/jmbi.1998.2238

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  182 in total

1.  TEM-1 beta-lactamase as a scaffold for protein recognition and assay.

Authors:  Daniel Legendre; Bénédicte Vucic; Vincent Hougardy; Anne-Lise Girboux; Christophe Henrioul; Julien Van Haute; Patrice Soumillion; Jacques Fastrez
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

2.  Isoform-specific monobody inhibitors of small ubiquitin-related modifiers engineered using structure-guided library design.

Authors:  Ryan N Gilbreth; Khue Truong; Ikenna Madu; Akiko Koide; John B Wojcik; Nan-Sheng Li; Joseph A Piccirilli; Yuan Chen; Shohei Koide
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

Review 3.  Generation and production of engineered antibodies.

Authors:  Sergey M Kipriyanov; Fabrice Le Gall
Journal:  Mol Biotechnol       Date:  2004-01       Impact factor: 2.695

4.  Regulation of Proteasomal Degradation by Modulating Proteasomal Initiation Regions.

Authors:  Kazunobu Takahashi; Andreas Matouschek; Tomonao Inobe
Journal:  ACS Chem Biol       Date:  2015-08-21       Impact factor: 5.100

5.  Chimeric fibronectin matrix mimetic as a functional growth- and migration-promoting adhesive substrate.

Authors:  Daniel C Roy; Susan J Wilke-Mounts; Denise C Hocking
Journal:  Biomaterials       Date:  2010-12-24       Impact factor: 12.479

6.  Recombinant adenovirus type 5 vectors that target DC-SIGN, ChemR23 and alpha(v)beta3 integrin efficiently transduce human dendritic cells and enhance presentation of vectored antigens.

Authors:  Casey A Maguire; Ramil Sapinoro; Natasha Girgis; Sol M Rodriguez-Colon; Servio H Ramirez; Jennifer Williams; Stephen Dewhurst
Journal:  Vaccine       Date:  2005-08-24       Impact factor: 3.641

7.  Directed Evolution to Engineer Monobody for FRET Biosensor Assembly and Imaging at Live-Cell Surface.

Authors:  Praopim Limsakul; Qin Peng; Yiqian Wu; Molly E Allen; Jing Liang; Albert G Remacle; Tyler Lopez; Xin Ge; Brian K Kay; Huimin Zhao; Alex Y Strongin; Xiang-Lei Yang; Shaoying Lu; Yingxiao Wang
Journal:  Cell Chem Biol       Date:  2018-01-27       Impact factor: 8.116

8.  64Cu-Labeled Gp2 Domain for PET Imaging of Epidermal Growth Factor Receptor.

Authors:  Max A Kruziki; Brett A Case; Jie Y Chan; Elizabeth J Zudock; Daniel R Woldring; Douglas Yee; Benjamin J Hackel
Journal:  Mol Pharm       Date:  2016-10-10       Impact factor: 4.939

Review 9.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

10.  GSK3732394: a Multi-specific Inhibitor of HIV Entry.

Authors:  David Wensel; Yongnian Sun; Jonathan Davis; Zhufang Li; Sharon Zhang; Thomas McDonagh; David Langley; Tracy Mitchell; Sebastien Tabruyn; Patrick Nef; Mark Cockett; Mark Krystal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.